BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21297223)

  • 1. Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.
    Merz H; Kaehler C; Hoefig KP; Branke B; Uckert W; Nadrowitz R; Cerny-Reiterer S; Herrmann H; Feller AC; Valent P
    Oncotarget; 2010 Jun; 1(2):104-119. PubMed ID: 21297223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
    Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
    Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
    Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
    Bischof D; Pulford K; Mason DY; Morris SW
    Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
    Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
    Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
    J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
    Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M
    Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.
    Sotlar K; Cerny-Reiterer S; Petat-Dutter K; Hessel H; Berezowska S; Müllauer L; Valent P; Horny HP
    Mod Pathol; 2011 Apr; 24(4):585-95. PubMed ID: 21186345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.
    Kuefer MU; Look AT; Pulford K; Behm FG; Pattengale PK; Mason DY; Morris SW
    Blood; 1997 Oct; 90(8):2901-10. PubMed ID: 9376569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
    Pulford K; Lamant L; Morris SW; Butler LH; Wood KM; Stroud D; Delsol G; Mason DY
    Blood; 1997 Feb; 89(4):1394-404. PubMed ID: 9028963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions.
    Elmberger PG; Lozano MD; Weisenburger DD; Sanger W; Chan WC
    Blood; 1995 Nov; 86(9):3517-21. PubMed ID: 7579458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis.
    Sarris AH; Luthra R; Papadimitracopoulou V; Waasdorp M; Dimopoulos MA; McBride JA; Cabanillas F; Duvic M; Deisseroth A; Morris SW; Pugh WC
    Blood; 1996 Sep; 88(5):1771-9. PubMed ID: 8781434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
    Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R
    J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.
    Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA
    Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.
    Maes B; Vanhentenrijk V; Wlodarska I; Cools J; Peeters B; Marynen P; de Wolf-Peeters C
    Am J Pathol; 2001 Jun; 158(6):2185-93. PubMed ID: 11395396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
    Giuriato S; Foisseau M; Dejean E; Felsher DW; Al Saati T; Demur C; Ragab A; Kruczynski A; Schiff C; Delsol G; Meggetto F
    Blood; 2010 May; 115(20):4061-70. PubMed ID: 20223922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
    Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.